New — registered 16 November 2026. This is a developing story and this page is a plain status tracker. The medicine is registered, which is not the same as being on pharmacy shelves, and no Australian price has been published. We will update as details are confirmed rather than guess at them.
The short version: Foundayo is an oral GLP-1 — taken by mouth, not injected. It was entered on the ARTG on 16 November 2026, sponsored by Eli Lilly Australia. Unusually, it is registered here for both weight management and type 2 diabetes. It is prescription-only (Schedule 4), not on the PBS (so a private script paid in full), has no published Australian price, and carries the TGA's Black Triangle marker for additional safety monitoring.
Registered16 Nov 2026ARTG entry date
PBS statusNot listedPrivate script, paid in full
ScheduleS4Prescription only
Australian priceNot publishedSee cost section below

What has actually been registered

Twelve separate entries went on the register on the same day, across two oral dosage forms. Every entry links to its own record on the TGA website if you want to read the original.

StrengthARTG entry
0.8 mg521939
2.5 mg521944
5.5 mg521948
9 mg522875
14.5 mg521941
17.2 mg521942
Both forms are taken by mouth. The register does not state which form is intended for which use, so we are not going to tell you — that will become clear when the Product Information is published, and your prescriber and pharmacist will know which applies to a given script. Sponsor: Eli Lilly Australia Pty Ltd. The 9 mg tablet record lists a pack size of 30 tablets, stored below 30 °C.

What it is registered for

The Australian registration covers two separate uses. In summary, and in our own words:
1. Weight management. As an addition to a healthy diet and physical activity, for adults with a body mass index at or above 30, or between 27 and 30 where at least one weight-related condition is also present. The register gives examples of such conditions, including high blood pressure, abnormal blood fats, prediabetes, type 2 diabetes, obstructive sleep apnoea and cardiovascular disease.
2. Type 2 diabetes. As an addition to a healthy diet and physical activity for adults whose type 2 diabetes is not sufficiently controlled — either on its own where metformin is not suitable because of intolerance or a contraindication, or alongside other diabetes medicines.
This is broader than the United States approval, which covers weight management only. If you are reading American coverage of this medicine, it does not describe the Australian position. The United Kingdom and the European Union registrations also cover both uses.
Whether any of this applies to an individual is a clinical decision, not something a web page can answer. We describe what is registered; we do not advise who should take it.

▼ Under additional monitoring (Black Triangle)

The register records Foundayo as part of the TGA's Black Triangle Scheme. The black triangle marks medicines under additional monitoring — typically newly registered ones — and signals that the TGA particularly wants adverse events reported so the safety picture can be built up in real use.
This is routine for a new medicine. It is not a warning that something is wrong with it.
Suspected side effects can be reported to the TGA on 1800 020 653, or online through the report a problem page. Patients and carers can report directly — you do not need to go through a doctor.

Cost and the PBS

Not on the PBS. Registration on the ARTG and subsidy under the PBS are two separate processes, and the first says nothing about the second. No orforglipron submission appears on the published PBAC meeting agendas, including November 2026. In practice that means a private prescription paid in full — the same position as the Wegovy and Mounjaro injections for weight management.
No Australian price has been published. Figures have been circulating online. We checked them and could not substantiate any against a primary or reliable source, so we are not printing one — a wrong number here would send people into a pharmacy with the wrong expectation. When a verified Australian price exists, it goes on this page with its source.
For context, privately prescribed weight-management medicines in Australia have typically run to several hundred dollars a month, and prices differ between pharmacies. Ask your pharmacy for a current quote once the medicine is actually supplied, and ring more than one.
⚖️ Compare weight management options 💊 PBS price checker

When you can actually get it

Registered is not the same as supplied. An ARTG entry means the medicine may lawfully be supplied in Australia. It does not mean stock has reached pharmacies, and the sponsor decides when a launch happens.
No launch date had been announced at the time of writing. Supply of weight-management medicines in Australia has been patchy in the past, so even after launch, availability may take time to settle.
How access works: it is prescription-only, so you would see a doctor to discuss whether it is appropriate for you, and fill the script at a pharmacy. We do not advise for or against any medicine — that is a conversation for you and your GP.

⚠️ If someone offers to sell it to you now

Registered, widely reported, not yet on shelves — that gap is exactly when scams, counterfeits and “alternatives” appear. Three things worth knowing:
1. Advertising it to the public is illegal. In Australia it is unlawful to advertise a prescription-only medicine to the public. If you see this medicine being advertised to consumers, that advertising is illegal, and it may point to a counterfeit product or a scam.
2. Compounded GLP-1 products are not a legal substitute. From 1 October 2024, amendments to Schedule 5, Item 6 of the Therapeutic Goods Regulations 1990 removed GLP-1 receptor agonists from the pharmacy compounding exemption, so these products can no longer be compounded by pharmacists and supplied to patients.
3. Buy only from an Australian pharmacy against a valid script. The TGA has previously detected counterfeit and substandard weight-management products entering Australia, including a “compounded” product linked to a patient hospitalisation. If you have a product of unknown origin, take it to your local pharmacy for safe disposal.
This is regulatory and consumer information, not medical advice, and not a comment on any individual product or provider. Whether any medicine suits you is a decision for you and your doctor.

Yes. Foundayo (orforglipron) was entered on the Australian Register of Therapeutic Goods on 16 November 2026, sponsored by Eli Lilly Australia Pty Ltd, across twelve entries and two oral dosage forms. Registration means it may lawfully be supplied here. It does not mean it has reached pharmacies.

No. It is not PBS-listed, so it is a private prescription paid in full. TGA registration and PBS subsidy are separate processes, and no orforglipron submission appears on the published PBAC meeting agendas, including November 2026. More broadly, no GLP-1 medicine is currently PBS-subsidised for weight management in the general population. If this changes, we will update this page.

No Australian price had been published at the time of writing. Figures circulating online could not be substantiated against any primary or reliable source, so we are deliberately not printing one. As a private script the full cost falls to the patient. Privately prescribed weight-management medicines in Australia have typically run to several hundred dollars a month, and pharmacies differ — ask for a current quote once it is supplied, and ring more than one.

By mouth, not injected. The register records two oral forms — film-coated tablets and hard capsules — across a range of strengths. It is the second oral GLP-1 registered in Australia for weight management, after the oral semaglutide (Wegovy) tablet registered on 3 November 2026.

Those three are injections given weekly. Foundayo is taken by mouth. They also differ in active ingredient — semaglutide for Ozempic and Wegovy, tirzepatide for Mounjaro, orforglipron for Foundayo — and in what each is registered for. Our GLP-1 medicines in Australia page compares them side by side. Which, if any, suits a particular person is a decision for them and their GP.

NEXVOUND was the proposed Australian brand name shown on the TGA's earlier "under evaluation" listing, while the application was still being assessed. The medicine was registered under the name FOUNDAYO, matching the brand used in the United States, United Kingdom and Europe. Searching for the old proposed name will not find the current register entries.

We are not going to list them here from overseas material. The authoritative Australian source is the Consumer Medicine Information (CMI) and Product Information for the Australian product, which you can look up on the TGA website or ask your pharmacist for. Note also that this medicine is under additional monitoring (see the Black Triangle section above), so the safety picture will continue to develop. If something new and worrying starts after beginning any medicine, contact your GP or pharmacist; if it feels urgent, get medical help promptly.

Not currently. The type 2 diabetes use is part of the Australian registration, but registration is not subsidy — there is no PBS listing for this medicine for any indication, so it would be a private script either way. Some other GLP-1 medicines are PBS-subsidised for type 2 diabetes under Authority Required criteria; your GP can explain which options are subsidised for your situation.

You might also like

Last verified against sources: 17 November 2026 — ARTG entries confirmed directly on the TGA register one day after registration. Still to come: Product Information and Consumer Medicine Information publication, an Australian launch date, a verified Australian price, and any PBAC submission. Each will be added here once it exists.